NEW YORK (GenomeWeb News) – Vermillion today announced that all four non-contingent contract claims with Bio-Rad Laboratories stemming from Vermillion's sale of its proteomics business in 2006 have been settled.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.